Abstract
Vol.37 No.2
- « prev
- ↑Table of Contents
- next »
PGT-A should not be used as a universal screening test, but should be used in limited cases within IRB-approved trials
JMOR, 37(2) 87-88, 2020
The purpose of preimplantation genetic testing for aneuploidy (PGT-A) is to improve the clinical pregnancy rate and decrease the miscarriage rate by screening for aneuploidy of the embryo. Theoretically, the clinical success rate with PGT-A should be better than that of a traditional morphological examination. However, according to a recent multi-center randomized controlled trial, the benefits of PGT-A in ART practice have not been demonstrated. Trophectoderm biopsy of blastocysts may have methodology-dependent limitations which prevent accurate examination for euploidy of the embryo. The widening gap between the rapid advances in genome information that can be obtained by the examination and the unreached consensus on their clinical utilization may hold bioethical risks. Therefore, at the present time, the clinical use of PGT-A should be restricted to Institutional Review Board-approved trials.
